Advertisement

BIO

Bio-Rad Laboratories, Inc.

Healthcare · USD

Set alert

Price alert · BIO

All alert types
372.18 USD -12.22 -3.18%
As of Oct 30, 2026 Extended hours 372.18 0.00%
Bid
371.39 × 80
Ask
373.39 × 40
368.45 Day range 381.29
241.71 52-week range 390.34
YTD
+22.84%
1 year
+22.18%
Open
381.09
Prev close
384.40
Mkt cap
9.96B
Vol
183.09K
Avg vol
255.45K
EPS
7.89
P/E
47.17
Div yield
0.00%
More statistics
Low
368.45
High
381.29
Forward P/E
38.14
Beta
1.07
Short ratio
4.17
Inst. own
91.77%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
374.89
200-d avg
313.14
1y target
335.00

2Y chart

Chart tools
Interval
BIO two-year price chart211.4257.6303.8350.0396.2Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
9.94B
Enterprise value
10.03B
Trailing P/E
47.11
Forward P/E
38.14
PEG ratio
4.01
Price / sales
3.84
Price / book
1.39
EPS (TTM)
7.89
Beta
1.07
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
8.59%
Revenue (TTM)
2.59B
Revenue growth
-0.10%
Free cash flow
283.19M
Total cash
1.62B
Total debt
1.37B
Return on equity
3.11%
Shares outstanding
21.68M
Short % of float
6.91%
50-day average
374.89
200-day average
313.14

Analyst view

Consensus: hold

Hold
Price target (mean) 335.00 -10.0% downside
Target (low)
280.00
Target (mean)
335.00
Target (high)
390.00
Ratings (0m) 3 1 buy · 1 hold · 1 sell
  • Strong buy1
  • Buy0
  • Hold1
  • Sell0
  • Strong sell1

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 2.23.

Earnings history

Financials — quick view

All financials
BIO Revenue — quarterly 651.00M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BIO Net income — quarterly 371.40M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BIO EPS — quarterly 13.89
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

BIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 20262.23———
Aug 4, 2026Jun 30, 20261.752.62+0.87+49.71%
Apr 30, 2026Mar 31, 20261.971.89-0.08-4.06%
Feb 12, 2026Dec 31, 20252.572.51-0.06-2.33%
Oct 29, 2025Sep 30, 20252.302.26-0.04-1.74%
Jul 31, 2025Jun 30, 20251.932.61+0.68+35.23%

Upgrades / downgrades

BIO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 7, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026CitigroupmainNeutralNeutral
Aug 5, 2026RBC CapitalmainOutperformOutperform
Aug 5, 2026Wells FargomainEqual-WeightEqual-Weight
May 1, 2026Wells FargomainEqual-WeightEqual-Weight
Apr 7, 2026CitigroupdownBuyNeutral

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
bio-rad.com

News

Your note

Sign in to keep a note on BIO — it syncs with the Stock Master app.

Insider holders

BIO insider holders
InsiderRelationLatest transactionDateShares held
ALLISON SCHWARTZDirectorConversion of Exercise of derivative securitySep 3, 20261,734
BARRY JAMESOfficerConversion of Exercise of derivative securitySep 3, 20262,024
COREY COLLEENOfficerConversion of Exercise of derivative securitySep 4, 202519,550
CROWLEY MICHAEL WOfficerConversion of Exercise of derivative securityMar 13, 20258,171
DIVINCENZO JONATHAN PPresidentConversion of Exercise of derivative securityOct 22, 20262,881
ENGELHARDT EVA ANETTEOfficerConversion of Exercise of derivative securitySep 3, 20261,828

Institution ownership

BIO institution ownership
Holder% heldSharesValueReported
First Eagle Investment Management, LLC12.02%2,606,219968.77MJun 29, 2026
Blackrock Inc.7.84%1,698,929631.52MJun 29, 2026
Dimensional Fund Advisors LP4.36%944,548351.10MJun 29, 2026
Vanguard Capital Management LLC3.81%826,972307.40MJun 29, 2026
Vanguard Portfolio Management LLC3.77%816,198303.39MJun 29, 2026
Ariel Investments, LLC3.77%816,751303.60MJun 29, 2026

Fund ownership

BIO fund ownership
Holder% heldSharesValueReported
First Eagle Funds-First Eagle Global Fund8.67%1,878,739698.36MJul 30, 2026
SmallCap World Fund Inc4.29%930,906346.03MSep 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF2.99%648,604241.10MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.70%584,782217.37MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.95%423,193157.31MJun 29, 2026
Ariel Investment Trust-Ariel Fund1.61%349,270129.83MJun 29, 2026
Advertisement